Your search for "Genetics/Personalized Health" found 16 matches:
CU-GENES (Genetic Engagement, Education, and Screening)

Inclusion Criteria: • Over the age of 25 • At least one grandparent of Jewish ancestry OR be of Spanish ancestry with roots in the San Luis Valley • No prior genetic testing • No personal history of bone marrow transplants or blood cancers • Currently live in Colorado OR New Mexico ...

Protocol #: 23-0584

An Operationally Seamless, Randomized Phase 2/3 Study Consisting of a Phase 2 Single-Blind, Dose-Evaluation Phase and a Phase 3 Double-Blind, Placebo-controlled Phase to Assess the Efficacy and Safety of Setrusumab in Subjects with Osteogenesis Imperfecta

A clinical trial examining the efficacy of Setrusumab in reducing fractures compared to a placebo for patients with Osteogenesis Imperfecta....

Protocol #: 22-2292

Location: Childrens Hospital Colorado

MECHANISTIC INVESTIGATION OF THERAPIES FOR DOWN SYNDROME REGRESSION DISORDER

Individuals with Down syndrome (DS) have an increased risk of numerous co-occurring conditions, including the neuropsychiatric condition known as Down Syndrome Regression Disorder (DSRD). A DSRD diagnosis often includes a sub-acute onset of catatonia, mutism, depersonalization, loss of abi...

Protocol #: 22-1992

Location: Childrens Hospital Colorado

Human Trisome Project

Additional information about this study can be found at www.trisome.org....

Protocol #: 15-2170

Location: Childrens Hospital Colorado, Outpatient CTRC, Outpatient CTRC, University of Colorado Hospital

Safety and efficacy of tofacitinib for immune skin conditions in Down syndrome

This study is designed to determine whether tofacitinib is a safe and effective treatment for immune skin conditions in adults with Down syndrome, and to further our understanding of the immune system in Down syndrome. This is a single arm, open-label study. All participants will receiv...

Protocol #: 19-1362

Location: Childrens Hospital Colorado, Outpatient CTRC, Outpatient CTRC, University of Colorado Hospital

Executive Functioning Outcome Measures for Down Syndrome

Protocol #: 19-2576

Location: Childrens Hospital Colorado

A Phase 3 Randomized Trial of Inotuzumab Ozogamicin (IND#:133494, NSC#: 772518) for Newly Diagnosed High-Risk B-ALL; Risk-Adapted Post-Induction Therapy for High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and Disseminated B-LLy

Protocol #: 19-2631

Location: Childrens Hospital Colorado

Role of Kv7 channels in the regulation of placental arteries vasoreactivity in mothers with Long QT syndrome (LQTS) Types 1 and 2

Protocol #: 20-0226

Location: Childrens Hospital Colorado, Memorial Hospital Central, University of Colorado Hospital

Inspiring New Science in Guiding Healthcare in Turner Syndrome (INSIGHTS) Registry

Participants who join the INSIGHTS Registry are agreeing to have their medical records be used for research. There are no additional study visits, etc. – participants just continue with their usual clinical care. In addition to the basic registry, individuals can join a recruitment list f...

Protocol #: 19-3027

Locations: Ann & Robert H. Lurie Children's Hospital of Chicago, Childrens Hospital Colorado, Childrens Hospital of Philadelphia, Childrens National Medical Center, University of North Carolina Children's Hospital, University of Texas Health Science Center at Houston

MicroRNA as a Maternal and Neonatal Biomarker to Predict Congenital Diaphragmatic Hernia Severity

Protocol #: 21-2481

Location: Childrens Hospital Colorado, University of Colorado Hospital

Multicentric Carpotarsal Osteolysis (MCTO): Natural History Study

Protocol #: 21-2606

Location: Childrens Hospital Colorado

Identifying novel therapeutic targets in MCTO by unbiased proteomics of patient plasma

Protocol #: 21-3367

Location: Childrens Hospital Colorado, Department Specific Free Standing Clinic

GALAXY: Generating Advancements through Longitudinal Analysis in X and Y Syndromes

Participants who join the GALAXY Registry are agreeing to have their medical records be used for research. There are no additional study visits, etc. – participants just continue with their usual clinical care. If participants are seen outside of Children’s Colorado, they can sign a Releas...

Protocol #: 20-0482

Location: Childrens Hospital Colorado, Outpatient CTRC

Prospective Clinical Assessment Study in Children with Achondroplasia: The PROPEL Trial

Protocol #: 23-0416

Location: Childrens Hospital Colorado

An Open-label, Randomized, Active-Controlled, Phase 3 Study of Setrusumab Compared With Bisphosphonates in Pediatric Subjects 2 to < 5 Years of Age With Osteogenesis Imperfecta Types I, III or IV

Protocol #: 23-0369

Location: Childrens Hospital Colorado

AttaCH: A Phase 2, Multicenter, Long-Term, Open Label Extension Trial Evaluating Safety, Tolerability, and Efficacy of Subcutaneous Doses of TransCon CNP Administered Once Weekly in Children and Adolescents with Achondroplasia

Protocol #: 23-0807

Location: Childrens Hospital Colorado